Key Points
- Insider selling: Nelson Sun sold 62,000 Aardvark Therapeutics shares at an average of $5.18, reducing his holdings by 63.61% to 35,475 shares. He also sold 14,754 shares the previous day.
- Mixed investment outlook: Aardvark reported a quarterly loss of $0.66 per share, better than the $0.87 consensus estimate, while analysts’ average rating remains “Hold” with a $15.33 target price.
- Legal overhang: The company faces a securities class-action lawsuit alleging that IPO materials omitted safety risks related to its ARD-101 drug candidate, including risks associated with a later FDA clinical hold.
Aardvark Therapeutics, Inc. (NASDAQ:AARD - Get Free Report) insider Nelson Sun sold 14,754 shares of Aardvark Therapeutics stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $5.00, for a total transaction of $73,770.00. Following the sale, the insider owned 97,475 shares in the company, valued at approximately $487,375. This trade represents a 13.15% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Nelson Sun also recently made the following trade(s):
- On Friday, September 11th, Nelson Sun sold 62,000 shares of Aardvark Therapeutics stock. The stock was sold at an average price of $5.18, for a total transaction of $321,160.00.
Aardvark Therapeutics Stock Up 2.4%
Shares of AARD opened at $5.13 on Friday. The stock has a market cap of $112.26 million, a price-to-earnings ratio of -1.60 and a beta of 3.74. Aardvark Therapeutics, Inc. has a 12 month low of $3.35 and a 12 month high of $17.94. The company has a 50-day moving average price of $6.29 and a two-hundred day moving average price of $5.53.
Aardvark Therapeutics (NASDAQ:AARD - Get Free Report) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.66) earnings per share for the quarter, beating analysts' consensus estimates of ($0.87) by $0.21. Equities research analysts expect that Aardvark Therapeutics, Inc. will post -3.17 EPS for the current fiscal year.
Aardvark Therapeutics News Roundup
Here are the key news stories impacting Aardvark Therapeutics this week:
- Positive Sentiment: No company-specific clinical, regulatory, or financial improvement was reported in the latest updates. The absence of new adverse operating news may limit additional selling pressure.
- Neutral Sentiment: Several law firms—including Hagens Berman, Rosen Law Firm, SBS Law, Pomerantz, Faruqi & Faruqi, and Bernstein Liebhard—are soliciting investors to seek lead-plaintiff status by October 13, 2026. These announcements largely repeat the same underlying lawsuit rather than representing separate cases. Hagens Berman investor notice
- Neutral Sentiment: A reported September short-interest update showed zero shares sold short, but the figures appear incomplete or unreliable because the reported change was listed as “NaN.” It therefore provides little useful insight into trading direction.
- Negative Sentiment: The securities class action covers investors who bought Aardvark shares in or traceable to the February 2025 IPO, or who purchased securities between February 13, 2025, and May 14, 2026. The litigation alleges violations of federal securities laws by the company and certain officers and directors. Pomerantz class-action announcement
- Negative Sentiment: One investor notice alleges that IPO materials described Aardvark’s ARD-101 drug candidate as 99% restricted to the gut and reported no serious adverse events, while allegedly omitting safety risks that later led to an FDA clinical hold. These remain allegations, but the claims create potential legal costs, uncertainty, and reputational damage. AARD shareholder alert
Wall Street Analyst Weigh In
AARD has been the topic of several recent analyst reports. BTIG Research lowered Aardvark Therapeutics from a "buy" rating to a "hold" rating in a research note on Friday, May 15th. HC Wainwright reiterated a "neutral" rating and set a $6.00 price objective on shares of Aardvark Therapeutics in a research note on Monday, July 20th. Morgan Stanley reissued an "underweight" rating and set a $3.00 price objective (down from $7.00) on shares of Aardvark Therapeutics in a report on Friday, May 15th. Weiss Ratings upgraded shares of Aardvark Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Thursday, July 2nd. Finally, B. Riley Financial lowered their target price on shares of Aardvark Therapeutics from $8.00 to $7.00 and set a "buy" rating on the stock in a report on Friday, May 15th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, four have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $15.33.
Get Our Latest Report on AARD
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently modified their holdings of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in Aardvark Therapeutics during the 2nd quarter valued at $42,000. Persistent Asset Partners Ltd acquired a new position in Aardvark Therapeutics in the fourth quarter worth $56,000. New York State Common Retirement Fund acquired a new position in Aardvark Therapeutics in the second quarter worth $99,000. MetLife Investment Management LLC bought a new stake in shares of Aardvark Therapeutics during the fourth quarter worth $102,000. Finally, Bank of America Corp DE grew its holdings in shares of Aardvark Therapeutics by 72.9% during the second quarter. Bank of America Corp DE now owns 7,989 shares of the company's stock worth $108,000 after purchasing an additional 3,369 shares during the last quarter.
Aardvark Therapeutics Company Profile
(
Get Free Report)
Aardvark Therapeutics, Inc is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of small-molecule modulators of the retinoic acid receptor–related orphan receptor gamma (RORγ). RORγ plays a central role in T-helper 17 (Th17) cell differentiation and inflammatory processes. By targeting this transcription factor, Aardvark aims to address a range of autoimmune and immune-mediated diseases.
The company's lead programs consist of selective RORγ inverse agonists designed to suppress pathogenic Th17-driven responses in conditions such as psoriasis, inflammatory bowel disease and other chronic inflammatory disorders.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
